Xultophy : combination therapy for the treatment of type 2 diabetes
Chaplin, Steve
Chaplin, Steve
Citations
Altmetric:
Affiliation
George Eliot Hospital NHS Trust, Nuneaton
Other Contributors
Publication date
2015-09-04
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Xultophy is the first product to combine a basal insulin and an incretin mimetic for the treatment of type 2 diabetes. Here Steve Chaplin presents the clinical data relating to its efficacy and adverse events and Vinod Patel outlines its place in therapy.
Citation
Chaplin S, Patel V. Xultophy: Combination therapy for the treatment of type 2 diabetes. Prescriber. 2015 September;26(17):32-34. doi: 10.1002/psb.1382.
Type
Article